Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;30(8):514–520. [Article in Spanish] doi: 10.1016/S0212-6567(02)79090-2

Hepatitis víricas

JM Bayas 1,*, A Vilella 1
PMCID: PMC7679701  PMID: 12427376

The content is available as a PDF (305.4 KB).

Bibliografía

  • 1.Hadler S.C. Global impact of hepatitis A virus infection. Changing patterns. In: Hollinger F.B., Lemon S.M., Margolis H.S., editors. Viral hepatitis and liver diseases. Williams and Wilkins; Baltimore: 1991. pp. 14–20. [Google Scholar]
  • 2.Arnal J.M., Frisas O., Garuz R., Antoñanzas F. Cost-effectiveness of hepatitis A virus immunization in Spain. Pharmacoeconomics. 1997;12:361–373. doi: 10.2165/00019053-199712030-00008. [DOI] [PubMed] [Google Scholar]
  • 3.Salleras L.L. Estrategia vacunal frente a la hepatitis A en el adolescente en Catalunya. In: Campins M., Moraga F., editors. Vacunas 2000. Prous Science; Barcelona: 2000. pp. 163–177. [Google Scholar]
  • 4.Centers for Disease Control and Prevention Prevention of hepatitis A through active or passive immunization: recomendations of the Advisory Committee on Immunization Practices (ACIP) MMWR. 1999;48(RR-12):1–37. [PubMed] [Google Scholar]
  • 5.Departament de Sanitat i Seguretat Social . Manual de vacunacions. 3.ª. Gràfiques Viking S.A.; Barcelona: 2000. Generalitat de Catalunya. Col˙lecció: Quaderns de Salut Pública, 14. [Google Scholar]
  • 6.Zamir C., Rishpon S., Zamir D., Leventhal A., Rimon N., Ben-Porath E. Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. Eur J Clin Microbiol Infect Dis. 2001;20:185–187. doi: 10.1007/s100960100461. [DOI] [PubMed] [Google Scholar]
  • 7.Sagliocca L., Amorosos P., Stroffolini T., Adamo B., Tosti M.E., Lettieri G. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet. 1999;353:1136–1139. doi: 10.1016/S0140-6736(98)08139-2. [DOI] [PubMed] [Google Scholar]
  • 8.McMahon B.J., Beller M., Williams J., Schloss M., Tanttila H., Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med. 1996;150:733–739. doi: 10.1001/archpedi.1996.02170320079014. [DOI] [PubMed] [Google Scholar]
  • 9.Bond W.W. Survival of hepatitis B virus in the environment. JAMA. 1984;251:397–398. [Google Scholar]
  • 10.Centers for Disease Control Changing paterns of groups at high risk for hepatitis B in the United States. MMWR. 1988;37:429–432. 437. [PubMed] [Google Scholar]
  • 11.Bayas J.M., Bruguera M. Vacuna antihepatitis B. In: Salleras Ll., editor. Vacunaciones preventivas. Principios y aplicaciones. Masson S.A.; Barcelona: 1998. pp. 207–227. [Google Scholar]
  • 12.Centers for Disease Control Alternate two-dose hepatitis B vaccination schedule for adolescents aged 11–15 years. MMWR. 2000;49:261. doi: 10.1001/jama.283.16.2100-jwr0426-4-1. [DOI] [PubMed] [Google Scholar]
  • 13.Dentico P., Buongiorno R., Volpe A., Zavoianni A., Pastore G., Schiraldi O. Long-term immunogenicity safety and efficacy of a recombinant hepatitis B vaccine in healthy adults. Eur J Epidemiol. 1992;8:650–655. doi: 10.1007/BF00145379. [DOI] [PubMed] [Google Scholar]
  • 14.Stajich G.V., López G.P., Harry S.W., Sexson W.R. Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants. J Pediatr. 2000;136:679–681. doi: 10.1067/mpd.2000.105133. [DOI] [PubMed] [Google Scholar]
  • 15.Centers for Disease Control Recommendations regarding the use of vaccines that contain thimerosal as a preservative. MMWR. 1999;48:996–998. [PubMed] [Google Scholar]
  • 16.Hall A., Kane M., Roure C., Meheus A. Multiple sclerosis and hepatitis B vaccine?. Meeting report from a WHO/VHPB Meeting, Geneva, September 28–30, 1998; 1999. pp. 2473–2475. [DOI] [PubMed] [Google Scholar]
  • 17.Confavreux C., Suissa S., Saddier P., Bourdes V., Vukusic S. Vacci-nations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study. N Engl J Med. 2001;344:319–326. doi: 10.1056/NEJM200102013440501. [DOI] [PubMed] [Google Scholar]
  • 18.Pareja Bezares A., Álvarez Pasquín M.J., Batalla Martínez C., Comín Bertrán E., Gómez Marco J.J., Niño Martín V. Prevención de las enfermedades transmisibles. Aten Primaria. 1999;24(Suppl 1):99–117. [PubMed] [Google Scholar]
  • 19.Navas E., Bayas J.M., Taberner J.L., Salleras L.L. Eficiencia de la detección prevacunal de anti-HBc en los programas de vacunación antihepatitis B. Med Clin (Barc) 1992;99:641–644. [PubMed] [Google Scholar]
  • 20.Bruguera M., Bayas J.M., Vilella A., Tural C., González A., Vidal J. Imunogenicity and reactogenicity of a combined hepatitis A and hepatitis B vaccine in young adults. Vaccine. 1996;14:1407–1411. doi: 10.1016/s0264-410x(96)00089-8. [DOI] [PubMed] [Google Scholar]
  • 21.Liu J., Zhu L., Zhang X., Lu M., Kong Y., Wang Y. Expression, purification, immunological characterization and application of Escherichia coli-derived hepatitits C virus E2 proteins. Biotechnol Appl Biochem. 2001;34(Pt 3):109–119. doi: 10.1042/ba20010036. [DOI] [PubMed] [Google Scholar]
  • 22.Hunziker I.P., Zurbriggen R., Glueck R., Engler O.B., Reichen J., Dai W.J. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol Immunol. 2001;38:475–484. doi: 10.1016/s0161-5890(01)00083-9. [DOI] [PubMed] [Google Scholar]
  • 23.Forns X. Biología molecular del virus de la hepatitis C: implicaciones para el desarrollo de nuevas terapias y de una vacuna profiláctica. Med Clin (Barc) 2001;116:191–197. doi: 10.1016/s0025-7753(01)71766-6. [DOI] [PubMed] [Google Scholar]
  • 24.Epstein M.A. Reflections on Epstein-Barr virus: some recently resolved old uncertainties. J Infect. 2001;43:111–115. doi: 10.1053/jinf.2001.0898. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES